"Biogen's Decision to Discontinue Aduhelm: Impact on Alzheimer's Treatment"

Biogen will discontinue the sale of its Alzheimer's drug Aduhelm and halt the study needed for full FDA approval, shifting focus to other treatments. The drug, initially anticipated to be a blockbuster, faced challenges with limited evidence of efficacy and insurance coverage restrictions. Biogen will support the sale of another Alzheimer's treatment, Leqembi, which received full FDA approval. The company will incur a charge of about $60 million for shutting down the Aduhelm program, while patients may soon have another treatment option pending FDA review of a potential drug from Eli Lilly and Co.